Trazodone is serotonergic and is mainly metabolized by CYP3A4. The highest-risk interactions involve serotonin syndrome, excess sedation, and heart rhythm risk.
With: MAOIs (and IV methylene blue)
Risk: Contraindicated: High risk of serious serotonin toxicity.
Action: Do not combine. Allow 14 days between stopping an MAOI and starting trazodone, and 14 days between stopping trazodone and starting an MAOI.
With: Other serotonergic medications (SSRIs/SNRIs, certain opioids like tramadol, triptans, lithium, St. John’s wort, etc.)
Risk: Serotonin syndrome risk increases with combinations.
Action: Use caution, start low, and monitor. Educate on serotonin syndrome symptoms; seek urgent care for severe symptoms.
With: Alcohol, benzodiazepines, Z-drugs, sedating antihistamines, muscle relaxants
Risk: Additive CNS depression: Increased sedation, impaired driving, falls, breathing risk in vulnerable patients.
Action: Avoid or minimize combinations. If used together, use the lowest doses and monitor closely.
With: CYP3A4 inhibitors (examples: certain azole antifungals, some macrolide antibiotics, some HIV meds)
Risk: Can raise trazodone levels, increasing sedation, low blood pressure, and QT risk.
Action: Consider dose reduction and monitor for oversedation, dizziness, and cardiac symptoms.
With: CYP3A4 inducers (examples: carbamazepine, phenytoin, rifampin, St. John’s wort)
Risk: Can lower trazodone levels and reduce benefit.
Action: Monitor for loss of efficacy; dose adjustment or alternative may be needed.
With: Anticoagulants/antiplatelets/NSAIDs
Risk: Potential increased bleeding risk due to serotonin effects on platelets.
Action: Use caution and monitor for bruising, nosebleeds, GI bleeding, or unusual bleeding.
With: QT-prolonging medications or electrolyte-lowering agents
Risk: Higher risk of QT prolongation and arrhythmias.
Action: Avoid stacking QT-risk meds when possible; consider ECG and electrolyte monitoring in higher-risk patients.